Everyone is talking about Ozempic. But retatrutide is the drug that researchers are genuinely excited about. The early trial data is hard to ignore. We are talking about weight loss numbers that nobody expected to see from a single injectable drug.
So the question is real. Is retatrutide better than Ozempic? The short answer is that retatrutide produces more weight loss in trials. But the full picture is more useful than that simple answer, so let me walk you through what the science actually shows.
How Does Retatrutide Differ From Ozempic?
This is the most important thing to understand before comparing results.
Ozempic contains semaglutide. It works on one receptor in your body, the GLP-1 receptor. GLP-1 is a hormone your gut releases after you eat. It tells your pancreas to release insulin, slows how fast your stomach empties, and signals your brain that you are full. Ozempic mimics that signal. It works well. The clinical data backs that up.
Retatrutide works on three receptors at the same time. GLP-1, GIP, and glucagon. That triple action is why researchers call it a triple agonist. GIP is another gut hormone that boosts insulin release and may improve how your fat cells respond to the drug. Glucagon receptor activation increases how much energy your body burns at rest.
In my experience looking at the mechanistic research, the glucagon component is what separates retatrutide from everything else on the market. Glucagon tells your liver to burn more fuel. When you combine that with the appetite suppression from GLP-1 and GIP, you get a drug that hits weight loss from two directions at once. Less food going in, more energy going out.
Ozempic does one of those things. Retatrutide does both.
Is Retatrutide More Effective Than Ozempic for Weight Loss?
Yes, based on current trial data, retatrutide produces significantly more weight loss than Ozempic.
Here is what the numbers show. In a Phase 2 trial published in the New England Journal of Medicine in 2023, participants taking the highest dose of retatrutide lost an average of 24.2 percent of their body weight over 48 weeks. That is roughly 58 pounds for someone who starts at 240 pounds.
Ozempic at its approved 1mg dose produces around 15 percent body weight reduction in trials. Wegovy, which is semaglutide at a higher 2.4mg dose approved specifically for weight loss, produces around 15 to 17 percent weight loss over 68 weeks.
Retatrutide at its highest trial dose produced 24 percent weight loss in less time. That gap is large. What I found striking in the data was that the weight loss with retatrutide had not plateaued by week 48. The curve was still going down. That suggests the final number in longer trials could be even higher.
For context, bariatric surgery typically produces 25 to 30 percent total body weight loss. Retatrutide is approaching surgical outcomes from an injectable drug. That is what has researchers paying close attention.
Is Retatrutide FDA Approved Like Ozempic?
No. This is a critical difference right now.
Ozempic received FDA approval for type 2 diabetes management in 2017. Wegovy, the higher-dose semaglutide, received FDA approval for chronic weight management in 2021. Both drugs have gone through full Phase 3 trials and the complete regulatory review process.
Retatrutide is still in clinical trials. As of 2024, it is in Phase 3 trials for both obesity and type 2 diabetes. Eli Lilly, the company developing it, has not yet submitted a New Drug Application to the FDA. Approval is likely several years away at minimum.
What that means practically is that you cannot get a prescription for retatrutide right now through normal medical channels. Anyone offering it outside of a registered clinical trial is operating outside of approved medical practice. The drug has not completed the safety review process that Ozempic has.
This matters. Phase 2 trials are designed to test whether a drug works and find the right dose. They are not large enough or long enough to catch every safety signal. Phase 3 trials involve thousands of participants over longer periods specifically to find problems that smaller trials miss.
Does Retatrutide Have Fewer Side Effects Than Ozempic?
The side effect profiles look similar, not better.
The most common side effects reported in retatrutide trials are nausea, vomiting, diarrhea, and constipation. These are the same gastrointestinal side effects that Ozempic users report. In the Phase 2 trial, nausea occurred in about 40 to 50 percent of participants at higher doses. That is comparable to what semaglutide trials showed.
What I saw in the data was that side effects were dose dependent. Lower doses of retatrutide had fewer side effects. The highest doses that produced the most weight loss also produced the most nausea. That tradeoff exists with Ozempic too.
One area researchers are watching closely is heart rate. Retatrutide increased resting heart rate by around 4 to 5 beats per minute in trials. Semaglutide does this too, but the glucagon component in retatrutide may amplify this effect. For most healthy people this is not dangerous, but it is something that needs more data from longer trials.
Muscle loss is another concern with all GLP-1 drugs. When people lose weight rapidly, some of that weight is muscle. Early data suggests retatrutide may cause more lean mass loss than Ozempic simply because the total weight loss is greater. This is why resistance training and adequate protein intake matter enormously if you are on any of these drugs.
Can Retatrutide Replace Ozempic for Type 2 Diabetes Treatment?
The early data suggests it could be more effective for blood sugar control, but it cannot replace Ozempic right now because it is not approved.
In the Phase 2 trial, retatrutide reduced HbA1c levels significantly in participants with type 2 diabetes. HbA1c is the standard measure of average blood sugar over three months. Retatrutide brought it down by around 2 percentage points at higher doses. Ozempic typically reduces HbA1c by 1.5 to 2 percentage points. So the blood sugar results are comparable, possibly slightly better with retatrutide.
The glucagon receptor component is interesting here because glucagon normally raises blood sugar. You might expect activating the glucagon receptor to worsen diabetes. But the way retatrutide works, the GLP-1 and GIP effects dominate and the net result is better blood sugar control, not worse. The glucagon activation primarily drives fat burning rather than glucose release in this context.
Phase 3 diabetes trials are ongoing. Until those complete and the FDA reviews the data, retatrutide stays experimental for diabetes treatment.
When Will Retatrutide Be Available Compared to Ozempic?
Ozempic is available now. Retatrutide is realistically 3 to 5 years away from approval in most countries.
Eli Lilly started Phase 3 trials in 2023. Phase 3 trials typically run 2 to 4 years. After trials complete, the FDA review process takes another 6 to 12 months. Then comes manufacturing scale-up and distribution. A realistic approval window is 2027 to 2028 in the United States, with international approvals following after that.
Australia, where the Therapeutic Goods Administration runs drug approvals, typically follows FDA approvals by 12 to 24 months. So Australian availability could be 2029 or later.
The supply chain issue with Ozempic and Wegovy showed what happens when demand outpaces manufacturing. Retatrutide will face the same problem at launch. Even after approval, access will be limited initially.
So Which Drug Should You Actually Use Right Now?
If you qualify medically and your doctor recommends it, Ozempic or Wegovy are real options today. The data on semaglutide is extensive. We have years of real-world use data, not just trial data. We know the long-term cardiovascular benefits. The SUSTAIN and SELECT trials showed semaglutide reduces major cardiovascular events by around 20 percent in high-risk patients. That is a meaningful clinical outcome beyond just weight loss.
Retatrutide may eventually outperform semaglutide across every metric. The early data points that direction. But early data has surprised researchers before, in both directions. Phase 3 results sometimes look different from Phase 2 results when you scale up to thousands of participants.
What I found when looking at this from first principles is that the question most people are asking is the wrong one. The question is not which drug wins. The question is what you do alongside the drug. These medications suppress appetite and change your metabolic rate. They do not build muscle, improve your cardiovascular fitness, or teach you how to eat in a way that sustains results after you stop the drug.
The research on GLP-1 drugs consistently shows that people who combine medication with structured exercise and nutrition coaching maintain more of their weight loss and lose more fat relative to muscle. That holds for Ozempic and it will hold for retatrutide.
3 Things Most People Get Wrong About These Drugs
- They treat the drug as the whole solution. The drug changes your appetite and metabolism. What you do with that window determines your long-term outcome. People who use the reduced appetite to build better eating habits keep the weight off longer than people who just eat less of the same food.
- They ignore muscle loss. Rapid weight loss from any source, including these drugs, reduces muscle mass. Muscle drives your resting metabolic rate. Losing muscle makes it harder to maintain weight loss after stopping the drug. Resistance training 3 times per week and eating 1.6 to 2.2 grams of protein per kilogram of body weight are not optional if you want good body composition outcomes.
- They wait for the next drug instead of acting now. Retatrutide is not available. Waiting for it while carrying excess weight that is damaging your cardiovascular system, joints, and metabolic health is not a neutral choice. The best drug is the one that exists and that you can access today.
FAQ
Is retatrutide better than Ozempic for weight loss?
Based on Phase 2 trial data, yes. Retatrutide produced 24 percent body weight loss versus 15 to 17 percent for semaglutide. But retatrutide is not yet approved and Phase 3 data is still coming.
How does retatrutide differ from Ozempic?
Ozempic activates one receptor, GLP-1. Retatrutide activates three, GLP-1, GIP, and glucagon. The glucagon activation increases energy expenditure, which is why retatrutide produces more weight loss.
Is retatrutide FDA approved?
No. It is in Phase 3 trials as of 2024. Approval is expected no earlier than 2027 in the United States.
Does retatrutide have fewer side effects than Ozempic?
No. The side effect profile is similar, mainly nausea, vomiting, and diarrhea. Higher doses produce more side effects with both drugs.
Can retatrutide replace Ozempic for type 2 diabetes?
Not yet. Early data shows comparable or slightly better blood sugar control, but it needs full Phase 3 trial data and regulatory approval before it can be prescribed for diabetes.
When will retatrutide be available?
Realistically 2027 to 2028 in the United States, later in other countries including Australia.
If you are working on your weight, body composition, or metabolic health right now and want a structured approach that works alongside whatever medical treatment you are using, working with an online personal trainer gives you the exercise and nutrition framework that makes these interventions actually stick long term.
